Commentary

Gene and cell therapy as a new pillar of medicine

Read more

Letter from Milano: The challenges facing biotech from the coronavirus

Read more

What patients really want: involvement

Read more

Time for action against antimicrobial resistance

Read more

Why we all go to JP Morgan year after year

Read more

Technology for direct cell reprogramming

Read more

Computers take the hand of medicine

Read more

A strategy for using AI in pharma R&D

Read more

Novartis sets out its vision for pharma R&D

Read more

Battle looms over immunotherapy combination

Read more